Despite the recognition that a combination of specific BH3 mimetics with other drugs is necessary to achieve complete inhibition of the anti-apoptotic proteins Bcl-2, Bcl-xl, and Mcl-1 for the induction of apoptosis, these combinations have only hardly been used in clinical trials against PC to date. Here, BCL2L1 is linked to pachyonychia congenita.